Skip to main content
Clinical Trials/JPRN-UMIN000020291
JPRN-UMIN000020291
Completed
未知

Analysis of efficacy and safety of the stimulation of primary motor cortex with rTMS (TEN-P11) in the intractable neuropathic pain - Analysis of efficacy and safety of rTMS(TEN-P11) of primary motor cortex in the intractable neuropathic pain

Osaka University Medical Hospital0 sites144 target enrollmentDecember 25, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
Intractable neuropathic pain
Sponsor
Osaka University Medical Hospital
Enrollment
144
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 25, 2015
End Date
September 5, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Osaka University Medical Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\)Patients with dementia (MMSE\=\<24\) 2\)Patients with severe aphasia or higher brain dysfunction 3\)Patients with a major psychiatric disease 4\)Patients with a desire for suicide 5\)Patients with a history of epileptic attacks 6\)Patients with an implantable stimulator including a cardiac pacemaker, except an impantable spinal cord stimulator 7\)Patients with an implanted metal, except for titanium products, in their heads 8\)Patients with an implanted pump or mechanical heart 8\)Patients who cannot write questionaires 9\)Patients showing complete paralysis in painful evaluation area 10\)Patients without ability of agreements 11\)Patients receiving rTMS within a year before agreements 12\)Patients receiving other clinical trials or studies within 6 months before agreements 13\)Compliance of patients for prohibited drugs and treatments is under 80% 14\)Patients who are considered unsuitable for this clinical trial by a principal or sub investigator

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter
EUCTR2005-004451-35-NLGenzyme Europe BV99
Active, not recruiting
Not Applicable
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter - NDMultinodular goiterMedDRA version: 6.1Level: PTClassification code 10018498
EUCTR2005-004451-35-ITGenzyme Europe BV99
Active, not recruiting
Not Applicable
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiter
EUCTR2005-004451-35-DKGenzyme Europe BV99
Active, not recruiting
Phase 1
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiterodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the normal thyroid tissue.MedDRA version: 9.1Level: LLTClassification code 10043808Term: Thyrotropin
EUCTR2005-004451-35-FRGenzyme Europe BV99
Active, not recruiting
Not Applicable
Study to Evaluate the Dose, Safety and Effectiveness of Modified-Release Recombinant Human Thyroid Stimulating Hormone (MRrhTSH) When Used in Conjunction with Radioiodine for the Treatment of Multinodular Goiterodular goiter are clinically recognizable enlargements of the thyroid gland characterized by excessive growth and structural and or functional transformation of one or several areas within the normal thyroid tissue.MedDRA version: 9.1Level: LLTClassification code 10043808Term: Thyrotropin
EUCTR2005-004451-35-DEGenzyme Europe BV99